Related Experiment Video

Updated: May 29, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumocystis jirovecii pneumonia in developing countries

Y de Armas Rodríguez1, G Wissmann, A L Müller

  • 1Pathology Department, Institute of Tropical Medicine "Pedro Kourí", Ciudad de la Habana, Cuba.

Parasite (Paris, France)
|September 7, 2011
PubMed

Insights

Pneumocystis pneumonia (PcP) is a significant fungal infection in immunocompromised individuals. This review highlights its increasing prevalence in developing nations, particularly among AIDS patients, between 2002 and 2010.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Epidemiology

Background:

  • Pneumocystis pneumonia (PcP) is a severe opportunistic infection primarily affecting immunocompromised patients.
  • The epidemiology and clinical presentation of PcP are well-established in developed countries.
  • Limited data exists regarding the prevalence and characteristics of PcP in developing countries.

Purpose of the Study:

  • To review and synthesize existing literature on Pneumocystis pneumonia in developing countries.
  • To assess the prevalence and trends of PcP in various geographic regions.
  • To understand the clinical spectrum of PcP in the context of global health.

Main Methods:

  • A systematic review of published articles was conducted.
  • Studies focusing on African, Asian, and American countries were included.
  • Data on PcP prevalence and patient demographics were extracted and analyzed.

Main Results:

  • Pneumocystis pneumonia was confirmed as a frequent opportunistic infection in Human Immunodeficiency Virus (HIV)-positive patients across different regions.
  • A discernible increasing trend in PcP incidence was observed in developing countries from 2002 to 2010.
  • The study identified PcP as a significant health concern in resource-limited settings.

Conclusions:

  • Pneumocystis pneumonia remains a critical threat to immunocompromised populations globally.
  • There is an urgent need for increased awareness and improved diagnostics for PcP in developing nations.
  • Continued surveillance is essential to monitor trends and inform public health strategies for PcP management.

More Related Videos

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: